Key Spec Table
|Empirical Formula||CAS #|
Pricing & Availability
An invalid quantity was specified. The product quantity has been adjusted.
|Overview||A cell-permeable pyrazoloresorcinol compound that inhibits HSP90 ATPase activity (IC50 = 3.2 µM and 6.6 µM against human HSP90β and yeast HSP90, respectively) by targeting the enzyme's N-terminal ATP binding site. It exhibits no detectable effects against human Hsp70 or topoisomerase II even at concentrations as high as 100 µM and inhibits a panel of 20 commonly studied kinases only at much higher concentrations. Unlike 17-AAG (Cat. No. 100068), the antitumor activity of CCT018159 is not affected by the expression of NQ01/DT-diaphorase or P-glycoprotein.|
|Structure formula Image|
|Purity||≥98% by HPLC|
|Safety Information according to GHS|
|R Phrase||R: 36/37/38
Irritating to eyes, respiratory system and skin.
|S Phrase||S: 24/25-36/37/39
Avoid contact with skin and eyes.
Wear suitable protective clothing, gloves and eye/face protection.
|Product Usage Statements|
|Packaged under inert gas||Packaged under inert gas|
HSP90 Inhibitor, CCT018159 - CAS 171009-07-7 - Calbiochem MSDS
|Hardcastle, A., et al. 2007. Mol. Cancer Ther. 6, 1112.
Sharp, S.Y., et al. 2007. Cancer Res. 67, 2206.
Smith, N.F., et al. 2006. Mol. Cancer Ther. 5, 1628.
Dymock, B.W., et al. 2005. J. Med. Chem. 48, 4212.
Cheung, K.M., et al. 2005. Bioorg. Med. Chem. Lett. 15, 3338.
Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.